




Work Package n°7:
Appropriate use of antimicrobials in human and animals:
WP leaders:

FHI (Norway) & AEMPS (Spain)










Tasks	Leader
7.1 - Guidelines, tools and implementation methods for antibiotic stewardship	FHI (Norway)/AEMPS (Spain)
7.2- Workshop involving all the registered partners to discuss models of implementation	FHI (Norway)/AEMPS (Spain)
7.3- Qualitative evaluation of the level of implementation and acceptance of antibiotic stewardship at different levels of healthcare and in animals. Identify success factors and barriers	FHI (Norway)/AEMPS (Spain)
7.4.1 -Surveillance of AMR and AMC in humans	AEMPS (Spain) and SAS (Spain)
7.4.2.Surveillance of AMR in animals	ANSES (France) / ISS (Italy)





## 7.1 - Guidelines, tools and implementation methods for antibiotic stewardship



### **Contributors**

- Norwegian Directorate of Health;
- Conselleria de Salud del Govern de les Illes Balears (Spain);
- Fundación para la Formación e Investigfación Sanitarias de la Región de Murcia (Spain);
- The National Medicines Institute (Poland),
- The Norwegian Veterinary Institute;
- University of Foggia (Italy);
- Dutch Ministry of Health, Welfare and
- Statens Serum Institut (Denmark);
- University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj -Napoca (Romania);
- Robert Koch-Institute (Germany);
- Austrian Public Health Institute;
- Instituto Superiore Di Sanita (Italy);
- French Agency for Food, Environmental and Occupational Health & Safety (France);
- Croatian Institute of Public Health;
- The Hospital of Lithuanian University of Health Sciences Kauno Klinikos;
- National Public Health Centre (Lithuania).
- Federal Public Service Health, Food Chain Safety and Environment (Belgium)

## 7.1 - Guidelines, tools and implementation methods for antibiotic stewardship.



### Aims

### Human Health:

Update and expand the information available on the ECDC website to include information on existing guidelines, implementation methodology and work at different levels of the healthcare system.

### Animal Health:

Identify guidelines or tools that have been successful in controlling the consumption and resistance of antimicrobials in the animal population and what is needed next.

### Methods

- Survey
- Revision of available materials on the implementation of Antibiotic Stewardship Programmes

Survey

### Calls to Action

About us

Our wo

Get Involved

News

Results

ontact us

## Questionnaire for associations, vets, farmers and other professionals related to animal health

This questionnaire is a working JAMRAI), co-funded by the Hea

The Joint Action will enhance or

Survey to map the Antibiotic Stewardship Programmes in primary care, long-term care and hospitals in Europe

As part of the WP7, Appropriate use of antimicrobials in human and animals, we are developing a task that implies to collect information resources to assist in planning and implementing Antibiotic Stewardship Programmes at all levels of healthcare and with different levels of available resources. Therefore, we have designed a survey to complement the information already available on this topic. The survey is currently being distributed to relevant respondents within the Member States and Associated Countries. In order to identify what has been effective and what hasn't worked, we need to know what has already been implemented; under what conditions this occurred and what the outcomes were.

Contact person for the survey:

Live Storehagen (Norwegian Institute of Public Health - NIPH), Oliver Kacelnik (NIPH), Paloma Crespo Robledo (Spanish Agency of Medicines and Medical Devices- AEMPS) and Antonio López Navas (AEMPS)

Contact: live.storehagen@fhi.no and pcrespo\_externo@aemps.es

## 7.1 - Guidelines, tools and implementation methods for antibiotic stewardship




### Human health


- ✓ Survey:
  - Description:
    - Identification of respondents for the questionnaire
    - Development questionnaire and partner feedback
    - Utilisation of electronic tools (QuestBack)
    - Distribution of questionnaire, 14 May 20 July 2018
  - Progress: finished
  - Achivements:
    - Presented and discussed in WS held yesterday (7/11/18).

### Short summary of survey



Total number of respondents:	95
Number of countries:	28
Number of respondents - hospitals	60
Number of respondents - primary care	56
Number of respondents - long-term care	22





## 7.1 - Guidelines, tools and implementation methods for antibiotic stewardship



### Human health

- ✓ Revision of available materials on the implementation of Antibiotic Stewardship Programmes
  - Description:
    - Perform protocol for development of the task
    - Increase involvement from partners in this task: videoconference, minutes and presentation
    - Mapping
    - Layout and publication in website
  - Progress: finished
  - Achivements:
    - First deliverable release on EC portal: 7.1
    - Directory available and downloadable in eu-jamrai.eu/results





## Guidelines, tools and implementation methods for antibiotic stewardship

Below is a collection of documents about implementation of antibiotic stewardship at different levels of care. Inside each list you can access the original documents. This is not an exhaustive list but is intended as a resource-bank. The links are correct at the time of publication but may change over time.

LISTS BY LEVEL OF CARE
All levels of care (Hospital care, Community/primary care and Long-term facility care)

Hospital care

### 7.1 - Guidelines, tools and implementation methods for antibiotic stewardship



### Animal health

- ✓ Survey:
  - Description:
    - Identification of respondents for the questionnaire
    - Development questionnaire, partner stakeholder feedback
    - Utilisation of electronic tools (Survey Monkey)
    - Distribution of questionnaire: 16 March 15 June 2018
  - Progress: finished
  - Results: will need to be publish analysing the guidelines and opinions gathered

Appropriate use of antimicrobials in animals. WP7. European Joint Action on AMR and HCAI (EU-JAMRAJ)

QUISTENNABLE FOR ASSOCIATIONS, VEIS, FAIRADIS AND OTHER PROFESSIONALS HE ATTO TO ANDAM. HEALTH

This questionness is a vertical discussed proposed by <a href="https://www.dates.com/proposition.com/attention.com

The Jose Action will estimate obspection between theselve trains, the European Communication and its agreement and other automatican's organizations and will makin much target group to contribute to address the source of AME and Healthcare. Associated Information.

Enteress of this questionnates fits consolitation ones in effect the verse of associations, res, largers and office professionals related to around health on within guidelines or tools have been electrice to decrease administration consumption and together the profession and entered, and the paper or some to improvement.

The results will be remmarize globally, or proposition will remain answerseurs, and published within the EU-LAMEAD will and will be the base for a coming workshop on November 7th XIII. in Vienna, Austria.





#Questionnaire for associations, #vets,
#farmers and other professionals related to
#animal health that aims to collect data on
which guidelines or tools have been effective
to decrease #antimicrobials consumption
and improve the prudent use in animals
eu-jamrai.eu/campaigns/



### Distribution of the survey






Collaborating stakeholders, CVMP members


## Animal health Survey. Title: Questionnaire for Associations, vets, farmers and other professionals related to Animal Health












					Product	ion					Comp	anion	
Sector/ Type of animal expertise	Fish	Pigs	Poultry	Large Ruminant (milk)	Large Ruminant (meat)	Small ruminant (milk)	Small ruminant (meat)	Rabbit	Horse (meat)	Cat	Dog	Exotic	Horse
Academia, scientific society or													
association	11	42	35	43	35	27	27	7 13	9	24	27	13	18
Animal healthcare provider	14	82	55	136	118	52	78	3 37	30	246	251	83	87
Competent authorities	7	21	18	18	19	15	18	3 8	11	11	11	7	9
Farmers and animal keepers	4	15	13	16	27	5	30	3	4	7	9	0	8
Food industry	4	6	13	5	4	3	4	1 4	3	3	3	0	3
Pharmaceutical Veterinary Industry	2	4	4	5	4	3	3	3 2	3	6	5	1	3
Total	42	171	138	224	208	105	16:	1 67	60	298	307	104	129



\* 7. Specific measures needed to help to decrease antimicrobials consumption and to increase the prudent use. Indicate from 0 (strongly disagree) to 10 (strongly agree). 10 Good Measures needed practice guidelines Autoconsumption Control Tools Legislation Training Biosecurity measures Prescription guidelines Regional epidemiological maps for resistance of clinical pathogens Reduction / ban to use Regional epidemiological magistor. Reduction I ban to use of specific AM. sersitive test to help to those the ... Prevention tools such as vaccination of ... of specific AM on Prescription guidelines Legislation voluntary basis (for eg. Spanish Voluntary agreement to reduce colistin consumption to 5 mg/PCU) Rapid diagnosis test Sensitive test (to help to choose the best antimicrobial and avoid the use of CIAs) Prevention tools such as vaccination or optimised nutrition www.eu-jamrai.eu



## 7.2- Workshop involving all the registered partners to discuss models of implementation



- Human health WS in Vienna, 7 Nov 2018
- Animal health WS was cancelled due to lack of participants.

### Aims

- Discuss the findings of the JA survey on AS implementation
- Identify success factors in different settings
- Identify barriers to implementation
- Compile a report from the meeting to guide further interviews (task 7.3)
- Aid implementation of effective stewardship in Europe at all levels of health care

## 7.2- Workshop involving all the registered partners to discuss models of implementation







## 7.2- Workshop involving all the registered partners to discuss models of implementation



### Primary care - Barriers

- Motivation
- · Public vs private sector tension /incentives
- · LTCF under variable control
- · LTCF many different doctors
- · Poor sharing of information and data
- · Very few with electronic prescribing
- · Diagnostic uncertainty
- · Lack of diagnosis
- Lack of education of university students (AMR and HCAIs)

- · No role of the nurse in some countries
- Little of no role for community pharmacists
- · Lack of regional perspective
- · Ease of access to information
- · Guidelines have no legal clout
- · Over the counter prescribing
- · Expectations from patients

### Hospital care - Barriers

- · AMS team looked as a threat
- · Fatigue, time and finance / HR
- · Changing / Flow of staff / continuity of care / 24 hours availability
- · Lack of priority by leadership
- · Access to ATBs and communication
- · None-medical professionals
- · Lack of accountability to targets
- · AMR training across all healthcare professionals and public
- · Involvement of different professional societies
- · Integrating clinical informatics into clinical decision making process
- · Dedicated resources for quality audit and feedback
- IT and connectivity

### Primary care - Success factors

- Leadership
- · Central institutional support coordination HR, funding, expertise, skills sets
- Better awareness / education
- Uniform cross-systems guidelines / SOP / Software / Guidelines
- · Education / Peer to peer programmes
- · Indicators linked to incentive
- Good communication across primary care, LTCF and inter-professional groups
- · Access to hospital expertise (microbiologist etc.)
- · Small integrated systems
- · Good quality data systems
- · Public slogans and campaigns
- · Electronic alert system

### Hospital care - Success factors

- Leadership
- · AMS leader position of authority
- · Broad clinical engagement
- · Agreed guidelines / SOP and vision
- Training on stewardship on clinical meetings
- · Joining a EU mentor programme
- Reputation / Senior leadership
- · Accountability and responsibility

- · Regular audit and feedback
- IT and connectivity
- Multidisciplinary
- · Set and short-term and long term goals
- Accreditation
- · Giving the pharmacist a review role
- Integration of the AMS and IPCT Team
- Good lab and epidemiology
- Clinically meaningful epidemiology data



7.3. Qualitative evaluation of the level of implementation and acceptance of antibiotic stewardship at different levels of healthcare and in animals. Identify success factors and barriers

# 7.3. Qualitative evaluation of the level of implementation and acceptance of antibiotic stewardship at different levels of healthcare and in animals. Identify success factors and barriers



### Contributors

- Norwegian Directorate of Health;
- Austrian Public Health Institute;
- The National Institute of Public Health (Czech Republic)
- Statens Serum Institut (Denmark)
- Robert Koch-Institute (Germany)
- The Hospital of Lithuanian University of Health Sciences Kauno Klinikos;
- The National Medicines Institute(Poland)
- Servicio Andaluz de Salud (Spain)
- Dirección General de Ordenación Profesional y Regulación Sanitaria. Departamento de Salud de la

Generalitat de Cataluña (Spain)

- Agence Nationale de la Securite Sanitaire de l'alimentation de l'Environnement et du travail (France)
- Folkhälsomyndigheten Public Health Agency of Sweden
- Conselleria de Salud del Govern de les Illes Balears (Spain)
- National Center of Infectious and Parasitic Diseases (Bulgaria)
- Federal Public Service Health, Food Chain Safety and Environment (Belgium)

## 7.3. Qualitative evaluation of the level of implementation and acceptance of antibiotic stewardship at different levels of healthcare and in animals. Identify success factors and barriers



### **Aims**

- To evaluate level of implementation of antimicrobial stewardship
- To identify barriers and success factors for implementation of antimicrobial stewardship
- to deliver a report of compliance of indicators of antibiotic use and resistance

In animal health need to contact with WP5 (WP5.3 on supervision)



# 7.4. Develop and test near real time surveillance of antimicrobials and multidrug resistant bacteria

7.4.1
Surveillance of AMC and AMR in humans

7.4.2
Surveillance of AMR in clinical pathogens of animals


### 7.4.1- Surveillance of AMC and AMR in humans



### **Aims**

- To develop a simple surveillance system of antibiotic use and resistance including feedback mechanisms for a shorter time-lag
- Select basic indicators for surveillance of antimicrobial consumption
- Select basic indicators for surveillance of antimicrobial resistance
- Reinforce participants surveillance systems to:
  - provide data on a quarterly basis
  - from Hospitals and/or Primary Care
  - at Regional or National scope


### eu-jamrai.sharefile.eu



Task 7.4.1.Pilot Real time Surveillance in Humans ....











Annex 1. How to calculate antibiotic pressure (consumption) indicators

Task 7.4.1

Joint Action Antimicrobial Resistance and Healthcare-Associated Infections

March 2018

### Nombre A



Data Collection Sheets



Guideline

### Piloting Guideline v3

Task 7.4.1. Develop and test near real time surveillance of antimicrobials and multidrug resistant bacteria: surveillance

> WP7 | Appropriate use of antimicrobials in humans and animals Leaders' acronym for Task 7.4.1 I SAS and AEMPS Editor(s) I SAS Reviewer(s) | AEMPS Dissemination level | All partners in this task Date | December 2017

> > v3 February 2018: definition of OBD included

### 7.4.1- Surveillance of AMC and AMR in humans



### Collaborators

### 11 countries (19 institutions)

- Bulgaria (1)
- Croatia (1)
- Czech Republic (1)
- Denmark (1)
- Germany (1)
- Greece (2)
- Italy (2)
- Lithuania (2)
- Poland (1)
- Portugal (1)
- Spain (6)

Geo scope	n	Rate
National scope	7	37%
Regional scope	12	63%

Setting scope	n	Rate
Hospitals+Primary Care	7	37%
Hospitals only	8	42%
Primary Care only	4	21%

Indicators	n	Rate
Antibiotic use only	3	16%
Antimicrobial resistance only	1	5%
Both AMC+AMR	15	79%

### 7.4.1- Surveillance of AMC and AMR in humans



### **Progress**

- Indicators for surveillance of AMC and AMR selected Dec/2017
- Guidelines developed and disseminated Dec/2017 (v.3 Feb/2018)
- Database and website developed Dec/2017
- Piloting 2018-2020 ongoing

### Preliminary results

- 47% of the participants (9/19) have provided 1st and 2nd quarters 2018 data
  - 67% of the respondents (6/9) provided complete geographical scope data
  - 33% of the respondents (3/9) provided partial (a sample of) geographical scope data
- 53% of the participants (10/19) have not provided data yet



- Start: April 2018
- General aim: Develop the surveillance of AMR in clinical bacterial pathogens of animals in a One Health approach.
- Contributors;
  - Sweden (SVA)
  - Norway (NVI)
  - Czech Republic (USKVBL)
  - Italy (ISS)
  - Spain (AEMPS & Ministry of Agriculture)
  - Greece (ESDY & Ministry of Agricultural development and Food)
  - France (ANSES)
  - Denmark (?)



### Specific objectives

- 1. Assess the surveillance systems in place if any on AMR in animal pathogens in each country
  - Questionnaire to describe national systems and teleconference
  - Evaluation of the French system by the OASIS method
- 2. Identify the main gaps and appropriate strategies for AMR surveillance in diseased animals depending on the country specificities
  - Questionnaire and teleconferences



- 3. Select appropriate AMR indicators in diseased animals in coherence with human. The choice of these indicators will allow correlating the animal data with the human data from subtask 7.4.1
  - Teleconference with human and veterinary partners
    - Adaptation of the preliminary list of target pathogens of public health relevance to monitor in the animal sector
    - Veterinary specific pathogens will also be included
    - Correlating animal and human data is not a priority
    - One health approach of clinical pathogen surveillance of animals:


« To decrease the public health impact of antimicrobial use in the veterinary sector, surveillance should be able to provide useful data for veterinarians to guide their prescriptions. »



- 4. Identify laboratory and technical capacities in each country
- 5. Assess the opportunities to combine the national surveillance systems into a pilot EU network
- 6. Draw guidelines for uploading, validation and management of the data
- 7. Provide global and specific recommendations to EU to build a European network covering AMR surveillance in diseased animals, including interface with AMR surveillance in human medicine

Uncovered yet





36

### Status of Stakeholders



### Meetings

Ν°	Meeting name	Туре	Date	Aim	Expected attendees
1	ECDC-task 7.4.1	TELECONFERENCE	19/10/2017	Inform ECDC about the aim and development of real-time surveillance of AMR and AMC	ECDC, AEMPS, SAS,
2	WP7 - PGEU	TELECONFERENCE	28/02/2018	Present WP7 and discuss possible involvment of stakeholder	FHI, PGEU (Jaime Wilconson), AEMPS
3	Vet+i	Face to Face. Vet+i headquarter	13/02/2018		Santiago DE ANDRÉS JUÁREZ, María JAUREGUÍZAR REDONDO , Patricia FERNANDEZ MARTINEZ, Pablo Hervás Calle (VET+I) and Paloma Crespo and Sara Sacristan (AEMPS)
3	EPRUMA	TELECONFERENCE	27/02/2018	Organize distribution of the survey. Task 7.1 in animal health	Myriam Alcain(EPRUMA) and Paloma Crespo (AEMPS)
4	Beam Alliance	TELECONFERENCE	23/03/2018	Information about WP7	Live Storehagen (NIPH, WP7), Marie Petit, Christine Årdal (NIPH, WP9) and Marie- Cecilie Ploy (INSERM, WP9)

### Status of the Stakeholders



### Contact by email

Organisation	Acronym	Contribution
European Centre for Disease Prevention and Control	ECDC	Tasks 7.1 and 7.4.1
The Standing Committee of European Doctors	СРМЕ	Human
DG Health and Food Safety - DG SANTE (former Food and Veterinary Office)	FVO	Animal
Union of European Veterinary Practitioners	EVPO	Animal. Task 7.1
European Platform for the Responsible Use of Medicines in Animals	EPRUMA	Animal. Task 7.1
European Union of General Practicioners	UEMO	Task 7.1
Pharmaceutical Group of the European Union (PGEU)	PGEU	Task 7.1 and 7.2
European Pharmaceutical Students Association	EPSA	Human
European Food Safety Agency	EFSA	Animal
Vet+i Foundation, Spanish Technology Platform for Animal Health	VET+I	Animal
Federation of European Microbiological Societies	FEMS	General
Federation of Veterinarians of Europe	FEV	Animal
MedTech Europe, the European trade association for the medical technology industries	MedTech Europe,	Human
BEAM Alliance	BEAM Alliance	-

### Risks encountered



### Foreseen

Risk n°	Description of risk	Proposed risk mitigation measures	Comments/updates
1	Lack of acceptance and cooperation from ECDC	_	Communication with ECDC has been successful
2	Lack of infrastructure	Pilot only in countries that can deliver data	A lot of hetegenerous data.  Difficult to analyse

### Risks encountered



### Unforeseen


Risk n°	Description of risk	Proposed risk mitigation measures	Comments/updates
1	Exhaustion from receiving too many surveys	Ask the ECDC Survey Committee to approve it.  Make animal survey as short as possible and easy to access	In the end, this was not a problem. Good sample of responders for each survey
2	Partners' commitment declines (when leaders request information or collaboration in contents approval)	Identification of communication focal points for each partner.  Fix deadlines  WP7 leaders close follow-up.  Coordinator support.	A <u>document with up-to-date</u> <u>information</u> about the tasks and deadlines was developed and sent to partners (also shared in Sharefile) 2 times during this year.  Informal meeting at the ECCMID conference in Madrid.  Videoconference for task 7.1 in june, all contributors
<b>3</b>	The evaluation of Resapath was highly time-consuming (around 3 months)	Another methodology should be used for assessing other surveillance	



### Next steps for year 2



- > Analyse more in detail findings from animal survey.
- > Develop task 7.3: first interviews in human health and contact with WP5 for animal health
- Task 7.4.1: first report of situation of the pilot study published in Website + first Milestone
- Task 7.4.2: the design of a preliminary European surveillance system should be finalized and under review from other European countries and relevant European institutions + first milestone







Co-funded by the Health Programme of the European Union







\* This presentation arises from the Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI), which has received funding from the European Union, under the framework of the Health Program (2014-2020) under the Grant Agreement N° 761296. Sole responsibility lies with the author and the Consumers, Health, Agriculture and Food Executive Agency is not responsible for any use that may be made of the information contained herein.